387 related articles for article (PubMed ID: 21790828)
1. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.
Avril T; Vauleon E; Hamlat A; Saikali S; Etcheverry A; Delmas C; Diabira S; Mosser J; Quillien V
Brain Pathol; 2012 Mar; 22(2):159-74. PubMed ID: 21790828
[TBL] [Abstract][Full Text] [Related]
2. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P
J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669
[TBL] [Abstract][Full Text] [Related]
3. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells.
Shaim H; Shanley M; Basar R; Daher M; Gumin J; Zamler DB; Uprety N; Wang F; Huang Y; Gabrusiewicz K; Miao Q; Dou J; Alsuliman A; Kerbauy LN; Acharya S; Mohanty V; Mendt M; Li S; Lu J; Wei J; Fowlkes NW; Gokdemir E; Ensley EL; Kaplan M; Kassab C; Li L; Ozcan G; Banerjee PP; Shen Y; Gilbert AL; Jones CM; Bdiwi M; Nunez-Cortes AK; Liu E; Yu J; Imahashi N; Muniz-Feliciano L; Li Y; Hu J; Draetta G; Marin D; Yu D; Mielke S; Eyrich M; Champlin RE; Chen K; Lang FF; Shpall EJ; Heimberger AB; Rezvani K
J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34138753
[TBL] [Abstract][Full Text] [Related]
4. Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.
Rapp C; Warta R; Stamova S; Nowrouzi A; Geisenberger C; Gal Z; Roesch S; Dettling S; Juenger S; Bucur M; Jungk C; DaoTrong P; Ahmadi R; Sahm F; Reuss D; Fermi V; Herpel E; Eckstein V; Grabe N; Schramm C; Weigand MA; Debus J; von Deimling A; Unterberg A; Abdollahi A; Beckhove P; Herold-Mende C
Acta Neuropathol; 2017 Aug; 134(2):297-316. PubMed ID: 28332095
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
Ozawa Y; Yamamuro S; Sano E; Tatsuoka J; Hanashima Y; Yoshimura S; Sumi K; Hara H; Nakayama T; Suzuki Y; Yoshino A
Biochem Biophys Res Commun; 2020 Apr; 524(3):723-729. PubMed ID: 32035622
[TBL] [Abstract][Full Text] [Related]
8. In vitro demonstration of salinomycin as a novel chemotherapeutic agent for the treatment of SOX2‑positive glioblastoma cancer stem cells.
Magrath JW; Raney WR; Kim Y
Oncol Rep; 2020 Aug; 44(2):777-785. PubMed ID: 32627023
[TBL] [Abstract][Full Text] [Related]
9. PNIPAAm-co-Jeffamine
Heffernan JM; McNamara JB; Borwege S; Vernon BL; Sanai N; Mehta S; Sirianni RW
Biomaterials; 2017 Oct; 143():149-158. PubMed ID: 28802102
[TBL] [Abstract][Full Text] [Related]
10. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells.
Iglesia RP; Prado MB; Cruz L; Martins VR; Santos TG; Lopes MH
Stem Cell Res Ther; 2017 Apr; 8(1):76. PubMed ID: 28412969
[TBL] [Abstract][Full Text] [Related]
11. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca
Shin HJ; Lee S; Jung HJ
J Cell Biochem; 2019 Apr; 120(4):6741-6752. PubMed ID: 30390339
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.
Kaluzova M; Bouras A; Machaidze R; Hadjipanayis CG
Oncotarget; 2015 Apr; 6(11):8788-806. PubMed ID: 25871395
[TBL] [Abstract][Full Text] [Related]
14. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
15. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways.
Bijangi-Vishehsaraei K; Reza Saadatzadeh M; Wang H; Nguyen A; Kamocka MM; Cai W; Cohen-Gadol AA; Halum SL; Sarkaria JN; Pollok KE; Safa AR
J Neurosurg; 2017 Dec; 127(6):1219-1230. PubMed ID: 28059653
[TBL] [Abstract][Full Text] [Related]
17. FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells.
Torres Á; Arriagada V; Erices JI; Toro MLÁ; Rocha JD; Niechi I; Carrasco C; Oyarzún C; Quezada C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208561
[TBL] [Abstract][Full Text] [Related]
18. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
[No Abstract] [Full Text] [Related]
19. Targeting Key Signaling Pathways in Glioblastoma Stem Cells for the Development of Efficient Chemo- and Immunotherapy.
Helweg LP; Storm J; Witte KE; Schulten W; Wrachtrup L; Janotte T; Kitke A; Greiner JFW; Knabbe C; Kaltschmidt B; Simon M; Kaltschmidt C
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361720
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
